Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

Open access

Abstract

BACKGROUND: Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer. METHODS: CTCs were analyzed in 2026 patients with early breast cancer before adjuvant chemotherapy and in 1492 patients after chemotherapy using the CellSearch System. After immuno-magnetic enrichment for cells expressing the epithelial-cell adhesion molecule, CTCs were defined as nucleated cells expressing cytokeratin and lacking CD45. The patients were followed for a median of 35 months (range = 0-54). Kaplan-Meier analyses and the log-rank test were used for survival analyses. All statistical tests were two-sided. RESULTS: Before chemotherapy, CTCs were detected in 21.5% of patients (n = 435 of 2026), with 19.6% (n = 136 of 692) of node-negative and 22.4% (n = 299 of 1334) of node-positive patients showing CTCs (P < .001). No association was found with tumor size, grading, or hormone receptor status. After chemotherapy, 22.1% of patients (n = 330 of 1493) were CTC positive. The presence of CTCs was associated with poor disease-free survival (DFS; P < .0001), distant DFS (P < .001), breast cancer-specific survival (P = .008), and overall survival (OS; P = .0002). CTCs were confirmed as independent prognostic markers in multivariable analysis for DFS (hazard ratio [HR] = 2.11; 95% confidence interval [CI] = 1.49 to 2.99; P < .0001) and OS (HR = 2.18; 95% CI = 1.32 to 3.59; P = .002). The prognosis was worst in patients with at least five CTCs per 30 mL blood (DFS: HR = 4.51, 95% CI = 2.59 to 7.86; OS: HR = 3.60, 95% CI = 1.56 to 8.45). The presence of persisting CTCs after chemotherapy showed a negative influence on DFS (HR = 1.12; 95% CI = 1.02 to 1.25; P = .02) and on OS (HR = 1.16; 95% CI = 0.99 to 1.37; P = .06) CONCLUSIONS: These results suggest the independent prognostic relevance of CTCs both before and after adjuvant chemotherapy in a large prospective trial of patients with primary breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/dju066

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Kaplan–Meier analysis according to the presence or absence (neg.) of peripheral blood circulating tumor cells (CTCs) before chemotherapy (CT). A) Disease-free survival. B) Overall survival. C) Distant disease-free survival. D) Breast cancer–specific survival. Two-sided log-rank test.
Figure 1. Kaplan–Meier analysis according to the presence or absence (neg.) of peripheral blood circulating tumor cells (CTCs) before chemotherapy (CT). A) Disease-free survival. B) Overall survival. C) Distant disease-free survival. D) Breast cancer–specific survival. Two-sided log-rank test.CC BY-NC · PubMed Central
Figure 2. Kaplan–Meier analysis according to the presence or absence of five or more peripheral blood circulating tumor cells (CTCs) before chemotherapy (CT). A) Disease-free survival. B) Overall survival. Two-sided log-rank test.
Figure 2. Kaplan–Meier analysis according to the presence or absence of five or more peripheral blood circulating tumor cells (CTCs) before chemotherapy (CT). A) Disease-free survival. B) Overall survival. Two-sided log-rank test.CC BY-NC · PubMed Central
Figure 3. The correlation of hazard ratios with increasing numbers of circulating tumor cells (CTCs) per 30mL of blood according to survival endpoints.
Figure 3. The correlation of hazard ratios with increasing numbers of circulating tumor cells (CTCs) per 30mL of blood according to survival endpoints.CC BY-NC · PubMed Central
Figure 4. Kaplan–Meier analysis for disease-free survival according to the presence (+) or absence (−) of peripheral blood circulating tumor cells (CTCs) before and after chemotherapy (CT). Two-sided log-rank test.
Figure 4. Kaplan–Meier analysis for disease-free survival according to the presence (+) or absence (−) of peripheral blood circulating tumor cells (CTCs) before and after chemotherapy (CT). Two-sided log-rank test.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 615

Metadata

Authors
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., Fehm, T., Schneeweiss, A., Lichtenegger, W., Beckmann, M. W., Friese, K., Pantel, K., & Janni, W.
Affiliations
University Hospital Heidelberg (DE)
Corresponding author
Rack, Brigitte
Venue
JNCI: Journal of the National Cancer Institute
Published
2014-05
Volume
106
Issue
5
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2169632044
Cited by
615
References
55
Citations by year
2026: 11 · 2025: 23 · 2024: 38 · 2023: 50 · 2022: 45 · 2021: 48 · 2020: 54 · 2019: 63 · 2018: 67 · 2017: 68 · 2016: 68 · 2015: 58 · 2014: 18
FWCI
22.66
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Chugai Pharmaceutical
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
circulating tumor cells, early breast cancer, prognostic factors, disease-free survival, overall survival, adjuvant chemotherapy, CellSearch, EpCAM, cytokeratin, CD45, lymph node status, CTC count, treatment response monitoring, metastatic breast cancer, hormone receptor status, tumor size and grade, risk stratification, risk-adapted treatment
MeSH terms
Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Deoxycytidine, Female, Fluorouracil, Humans, Lymphatic Metastasis, Middle Aged, Neoplastic Cells, Circulating, Neoplasm Staging, Prospective Studies, Epirubicin, Chemotherapy, Adjuvant, Immunomagnetic Separation, Taxoids, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. https://app.cochat.ai/papers/10.1093/jnci/dju066
The paper
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., Fehm, T., Schneeweiss, A., Lichtenegger, W., Beckmann, M. W., Friese, K., Pantel, K., & Janni, W. (2014). Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/dju066

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.